- Home
- AKRO
as 01-17-2025 4:00pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.0B | IPO Year: | 2019 |
| Target Price: | $46.83 | AVG Volume (30 days): | 842.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.32 - $37.00 | Next Earning Date: | 02-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Jonathan | AKRO | Chief Operating Officer | Jan 2 '25 | Sell | $28.03 | 10,000 | $280,330.00 | 218,083 | |
| Yale Catriona | AKRO | Chief Development Officer | Dec 16 '24 | Sell | $29.11 | 9,074 | $264,116.92 | 95,648 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Dec 16 '24 | Sell | $31.10 | 3,800 | $118,172.40 | 178,337 | |
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | Dec 16 '24 | Sell | $29.13 | 1,000 | $29,130.00 | 34,258 | |
| White William Richard | AKRO | Chief Financial Officer | Dec 10 '24 | Sell | $30.79 | 2,817 | $86,735.43 | 38,335 | |
| Yale Catriona | AKRO | Chief Development Officer | Dec 10 '24 | Sell | $30.79 | 2,810 | $86,519.90 | 95,648 | |
| Young Jonathan | AKRO | Chief Operating Officer | Dec 10 '24 | Sell | $30.79 | 2,503 | $77,067.37 | 218,083 | |
| Cheng Andrew | AKRO | President and CEO | Dec 10 '24 | Sell | $30.79 | 7,855 | $241,855.45 | 597,562 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Dec 10 '24 | Sell | $30.91 | 4,818 | $148,934.22 | 178,337 | |
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | Dec 10 '24 | Sell | $30.79 | 925 | $28,480.75 | 34,258 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
GlobeNewswire
12 days ago
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
12 days ago
Akero Therapeutics Insider Sold Shares Worth $280,330, According to a Recent SEC Filing
Insider Monkey
a month ago
Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
GlobeNewswire
2 months ago
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
MT Newswires
2 months ago
Citigroup Initiates Akero Therapeutics at Buy With $65 Price Target
GlobeNewswire
2 months ago
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
GlobeNewswire
2 months ago
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.